Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) open the trading on Wednesday, with great promise as it jumped 7.81% to $15.19, before settling in for the price of $14.09 at the close. Taking a more long-term approach, ZNTL posted a 52-week range of $9.56-$31.46.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
In the past 5-years timespan, the Healthcare sector firm’s annual sales growth was -20.00%. Meanwhile, its Annual Earning per share during the time was -50.05%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 18.03%. This publicly-traded company’s shares outstanding now amounts to $70.77 million, simultaneously with a float of $63.83 million. The organization now has a market capitalization sitting at $1.08 billion. At the time of writing, stock’s 50-day Moving Average stood at $13.41, while the 200-day Moving Average is $18.65.
Zentalis Pharmaceuticals Inc (ZNTL) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Biotechnology industry. Zentalis Pharmaceuticals Inc’s current insider ownership accounts for 10.05%, in contrast to 109.87% institutional ownership. According to the most recent insider trade that took place on Feb 12 ’24, this organization’s Chief Financial Officer sold 2,573 shares at the rate of 11.44, making the entire transaction reach 29,435 in total value, affecting insider ownership by 451,449. Preceding that transaction, on Feb 12 ’24, Company’s President sold 1,173 for 11.44, making the whole transaction’s value amount to 13,419. This particular insider is now the holder of 643,277 in total.
Zentalis Pharmaceuticals Inc (ZNTL) Earnings and Revenue Records
So, what does the last quarter earnings report of the company that was made public on 12/30/2023 suggests? It has posted -$0.93 earnings per share (EPS) not meeting the forecaster’s viewpoint (set at -$0.92) by -$0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.94 per share during the current fiscal year.
Zentalis Pharmaceuticals Inc’s EPS increase for this current 12-month fiscal period is 18.03% and is forecasted to reach -3.77 in the upcoming year.
Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) Trading Performance Indicators
Let’s observe the current performance indicators for Zentalis Pharmaceuticals Inc (ZNTL). It’s Quick Ratio in the last reported quarter now stands at 7.16. The Stock has managed to achieve an average true range (ATR) of 0.97.
In the same vein, ZNTL’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -4.56, a figure that is expected to reach -0.77 in the next quarter, and analysts are predicting that it will be -3.77 at the market close of one year from today.
Technical Analysis of Zentalis Pharmaceuticals Inc (ZNTL)
[Zentalis Pharmaceuticals Inc, ZNTL] recent stats showed that its last 5-days Average volume was poorer than the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 52.51% While, its Average True Range was 0.93.
Raw Stochastic average of Zentalis Pharmaceuticals Inc (ZNTL) in the period of the previous 100 days is set at 64.86%, which indicates a major fall in contrast to 74.77% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 75.51% that was lower than 97.25% volatility it exhibited in the past 100-days period.
